Date: Aug 1st, 2019

NanoMab To Initiate FIH for 99mTc-NM-02 at SGH

Shanghai, China, August 1st, 2019. NanoMab announced that it has decided to initiate FIH with 99mTc-NM-02, which is the company’s breast cancer program.

The kick off meeting was held at Shanghai General Hospital (SGH).

The primary objective of this study is to evaluate safety, tolerability and pharmacokinetics of 99mTc-NM-02.

99mTc-NM-02 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of HER2 expression in patients before or during HER2 targeted treatment